China-based BGI Genomics, an integral part of BGI Group, has signed a Memorandum of Understanding (MoU) with the Colombian National Cancer Institute (INC or Instituto Nacional de Cancerologia). This collaboration, which aims to foster research and further develop cutting-edge solutions based on genetic sequencing for early diagnosis of cervical and colorectal cancer, reflects a shared dedication to enhancing health outcomes in the region.

The Colombian National Cancer Institute was created in 1934, and for over seven decades the INC has been committed to the provision of a comprehensive approach to prevention, treatment, rehabilitation and research of cancer in the Colombian population. 

The MoU was formally inked at INC facilities by Dr Carolina Wiesner, INC Director, and Rainer Perez, alternate legal representative of BGI Genomics in Colombia. Marco Antonio Rincón, Latin America Business Director, BGI Genomics, notes: "BGI Genomics is 100 percent committed to providing cost-effective tools for the prevention and management of Human papillomavirus (HPV) and colorectal cancer to make a meaningful impact on the healthcare of Colombian people." As part of this MoU, BGI Genomics will also train INC personnel.